FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

Hexarelin

Examorelin / HEX

Growth Hormone Secretagogues

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

Wirkmechanismus

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection. GH response attenuates after 4-8 weeks (tachyphylaxis). Often cycled 8 weeks on, 4 weeks off.

Forschungsnotizen

Clinical Research Status

Hexarelin has been studied in multiple Phase 1/2 clinical trials for growth hormone deficiency, cardiac function, and aging-related decline, but has not progressed to regulatory approval. Italian cardiovascular research groups have published extensively on its direct cardiac effects independent of GH release. It remains available primarily as a research chemical, with clinical interest continuing in growth hormone secretagogue pharmacology and cardioprotection.

Key Published Findings

Studies demonstrate hexarelin produces the largest GH release among GHRPs, with peak GH levels of 30-50 ng/mL in healthy subjects after a single subcutaneous dose. Cardiovascular research shows hexarelin directly binds cardiac receptors (CD36), reducing cardiac fibrosis and improving ventricular function independent of GH/IGF-1 signaling. However, hexarelin shows significant tachyphylaxis with continuous use, with GH response diminishing substantially after 4-8 weeks of daily administration.

Safety Profile

Short-term studies show hexarelin is well-tolerated with common effects including transient hunger increase, flushing, and mild water retention consistent with GH elevation. The pronounced cortisol and prolactin co-stimulation distinguishes hexarelin from more selective GHRPs like ipamorelin. Tachyphylaxis (reduced response over time) limits its practical utility for sustained GH elevation, though pulsatile or intermittent protocols may partially mitigate this.

Comparison to Related Compounds

Hexarelin produces stronger GH release than GHRP-6 or GHRP-2 but with greater cortisol and prolactin stimulation, making it less selective. Compared to ipamorelin, which is highly GH-specific, hexarelin's broader receptor activation produces additional cardiovascular effects but more side effects. Unlike GHRH analogs (CJC-1295, sermorelin), hexarelin works through the ghrelin receptor pathway and can synergize with GHRH for amplified GH release.

Community Observations

Researchers note that hexarelin's rapid tachyphylaxis makes it poorly suited for continuous long-term GH elevation protocols. Its unique cardioprotective properties have generated interest separate from GH-releasing applications, particularly for post-myocardial infarction recovery research. Some protocols use hexarelin in short cycles (2-4 weeks) or intermittently to maximize GH response before tachyphylaxis develops.

Halbwertszeit

~1 hour

Rekonstitution

Bacteriostatic water (BAC)

Lagerung

Lyophilisiert

Refrigerate 2-8C up to 18 months.

Rekonstituierter

Refrigerate 2-8C. Use within 14 days.

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

ExamorelinHEX

Häufig gestellte Fragen

Was ist Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

Wie wirkt Hexarelin?

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

Wie ist der regulatorische Status von Hexarelin in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von Hexarelin?

~1 hour

Wie wird Hexarelin noch genannt?

Examorelin, HEX

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen